Skip to main content
. 2016 Mar 15;9:25. doi: 10.1186/s13045-016-0248-3

Fig. 3.

Fig. 3

Probability of (3a) relapse incidence (RI); (3b) non-relapse mortality (NRM); (3c) LFS, and (3d) OS after haplo-SCT for AL with or without PT-Cy + CsA/Tacro + MMF as GVHD prophylaxis